Published in Cancer Res on December 15, 2008
3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood (2011) 1.96
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
The high mobility group A1 gene: transforming inflammatory signals into cancer? Cancer Res (2010) 1.47
Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia (2013) 1.37
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood (2011) 1.36
HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One (2013) 1.25
HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One (2012) 1.25
HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics (2011) 1.19
STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res (2014) 1.17
Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res (2009) 1.15
HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One (2012) 1.15
MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells. Br J Cancer (2016) 1.14
HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol (2009) 1.14
Trichomonosis, a common curable STI, and prostate carcinogenesis--a proposed molecular mechanism. PLoS Pathog (2012) 1.10
Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma (2011) 1.07
LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun (2014) 1.06
HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs. Oncotarget (2014) 1.02
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep (2015) 0.92
Role of miRNA let-7 and its major targets in prostate cancer. Biomed Res Int (2014) 0.89
The Wnt/β-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer. Cell Biochem Funct (2012) 0.87
Annotation enrichment analysis: an alternative method for evaluating the functional properties of gene sets. Sci Rep (2014) 0.87
Hitting the bull's eye: targeting HMGA1 in cancer stem cells. Expert Rev Anticancer Ther (2014) 0.86
MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov (2015) 0.85
AKNA: another AT-hook transcription factor "hooking-up" with inflammation. Cell Res (2011) 0.85
HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Leuk Lymphoma (2013) 0.84
The high mobility group A1 molecular switch: turning on cancer - can we turn it off? Expert Opin Ther Targets (2014) 0.84
RNA-Mediated Regulation of HMGA1 Function. Biomolecules (2015) 0.83
Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J Immunol (2013) 0.83
The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology (2012) 0.82
HMGA1 levels influence mitochondrial function and mitochondrial DNA repair efficiency. Mol Cell Biol (2009) 0.82
Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Oncotarget (2016) 0.81
Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. Mediators Inflamm (2014) 0.78
Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. Leuk Lymphoma (2013) 0.77
HMGA1 amplifies Wnt signalling and expands the intestinal stem cell compartment and Paneth cell niche. Nat Commun (2017) 0.75
The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development. Curr Mol Med (2016) 0.75
Computational Detection of Stage-Specific Transcription Factor Clusters during Heart Development. Front Genet (2016) 0.75
Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis (2017) 0.75
RNA-Mediated Regulation of HMGA1 Function. Biomolecules (2015) 0.75
Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. Oncotarget (2015) 0.75
Self-inflicted DNA double-strand breaks sustain tumorigenicity and stemness of cancer cells. Cell Res (2017) 0.75
Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science (2002) 17.71
Stat3 as an oncogene. Cell (1999) 17.39
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol (1998) 4.09
Roles of HMGA proteins in cancer. Nat Rev Cancer (2007) 3.98
Molecular biology of HMGA proteins: hubs of nuclear function. Gene (2001) 3.69
Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol (2001) 2.72
HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol (2000) 1.71
Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther (2004) 1.70
The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res (2004) 1.67
The oncogenic properties of the HMG-I gene family. Cancer Res (2000) 1.57
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene (2005) 1.53
Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A (2000) 1.47
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res (2007) 1.42
The IFN-beta enhancer: a paradigm for understanding activation and repression of inducible gene expression. Cold Spring Harb Symp Quant Biol (1999) 1.34
Chromosomal aberrations induced by double strand DNA breaks. DNA Repair (Amst) (2005) 1.19
High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate (2004) 1.18
High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells. Oncogene (2004) 1.01
Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther (2008) 0.99
Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells. Biochim Biophys Acta (2000) 0.96
Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells. Oncogene (2004) 0.87
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell (2009) 8.97
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood (2009) 4.22
Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol (2005) 3.74
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res (2011) 3.58
Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells (2010) 3.53
Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood (2011) 3.43
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 3.24
Loop-mediated isothermal amplification for detection of African trypanosomes. J Clin Microbiol (2003) 3.23
Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood (2011) 3.21
Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells (2008) 3.14
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood (2008) 3.05
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Defining the role of Wnt/beta-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. Stem Cells (2005) 2.81
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 2.81
Stat3 regulates genes common to both wound healing and cancer. Oncogene (2005) 2.80
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell (2012) 2.61
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med (2010) 2.41
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res (2006) 2.41
Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology (2010) 2.31
Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol (2011) 2.28
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant (2010) 2.17
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res (2006) 2.11
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A (2005) 2.00
RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. Blood (2013) 2.00
In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. Proc Natl Acad Sci U S A (2008) 1.99
Expression and role of Foxa proteins in prostate cancer. Prostate (2006) 1.96
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res (2007) 1.96
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev (2005) 1.93
Role of Stat3 in regulating p53 expression and function. Mol Cell Biol (2005) 1.91
Human adult marrow cells support prolonged expansion of human embryonic stem cells in culture. Stem Cells (2003) 1.88
Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther (2003) 1.87
Do patients drop out prematurely from exposure therapy for PTSD? J Trauma Stress (2003) 1.83
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells (2010) 1.74
Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther (2004) 1.70
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene (2005) 1.70
A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem (2005) 1.70
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther (2006) 1.69
Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res (2004) 1.68
Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem (2003) 1.68
The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res (2004) 1.67
miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology (2010) 1.66
HES1 inhibits cycling of hematopoietic progenitor cells via DNA binding. Stem Cells (2006) 1.66
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res (2010) 1.64